Morgan Stanley has reiterated its overweight stance on Sun Pharma with a target price of ₹2,026 per share after the U.S. FDA approved a significant label update for UNLOXCYT, reflecting longer-term clinical data that shows improved patient outcomes. The brokerage said the updated label demonstrates a stronger objective response rate, with more than 50% of patients achieving meaningful clinical improvement, and presents encouraging duration-of-response (DOR) data.
Morgan Stanley highlighted that safety outcomes for the drug remained consistent with its class, with immune-mediated adverse events manageable and largely of low grade. The brokerage said the updated label strengthens the commercial potential of UNLOXCYT in the U.S. market, supporting Sun Pharma’s broader specialty strategy. The company has confirmed that U.S. commercial launch is scheduled for early 2026.
The note added that Sun Pharma continues to reinforce its leadership in branded generics and specialty therapeutics, with a pipeline that supports medium-term earnings visibility. Morgan Stanley believes the latest FDA development enhances confidence in the company’s speciality revenue ramp-up and strengthens its outlook heading into FY27.
Disclaimer: The views and recommendations above are those of Morgan Stanley. Business Upturn does not endorse them. Please consult a financial advisor before making investment decisions.
